PACB

1.27

1.55% -0.02

Dopo l'orario di chiusura: 1.27

Pacific Biosciences Of California Inc (PACB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché PACB Giù? Forum Previsione

Precedente Chiudi:

$1.29

Aprire:

$1.26

Volume 24 ore:

4.70M

Relative Volume:

0.73

Capitalizzazione di mercato:

$394.76M

Reddito:

$160.03M

Utile/perdita netta:

$-128.58M

Rapporto P/E:

-2.9756

EPS:

-0.4268

Flusso di cassa netto:

$-121.21M

1 W Prestazione:

-2.31%

1M Prestazione:

+10.43%

6M Prestazione:

-7.30%

1 anno Prestazione:

+4.10%

Intervallo 1D:

$1.25

$1.31

Intervallo di 1 settimana:

$1.25

$1.36

Portata 52W:

$1.07

$2.73

Pacific Biosciences Of California Inc Stock (PACB) Company Profile

Nome

Pacific Biosciences Of California Inc

Settore

Healthcare (1069)

Industria

Medical Devices (140)

Telefono

650-521-8000

Indirizzo

1305 O'BRIEN DRIVE, MENLO PARK, CA

Dipendente

485

Cinguettio

@pacbio

Prossima data di guadagno

2026-11-04

Ultimi documenti SEC

PACB's Discussions on Twitter

Compare PACB vs ABT, MDT, SYK, BSX, EW

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PACB Pacific Biosciences Of California Inc	1.27	400.97M	160.03M	-128.58M	-121.21M	-0.4268
ABT Abbott Laboratories	103.36	182.09B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	91.62	117.54B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	270.01	105.63B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	43.10	65.16B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	86.77	49.67B	6.30B	1.07B	1.09B	1.8406

Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-06	Downgrade	Barclays	Equal Weight → Underweight
2024-11-11	Downgrade	UBS	Buy → Neutral
2024-06-03	Ripresa	Jefferies	Buy
2024-04-22	Downgrade	JP Morgan	Overweight → Neutral
2024-04-18	Downgrade	Goldman	Buy → Neutral
2023-12-14	Iniziato	Guggenheim	Neutral
2023-12-14	Iniziato	Stephens	Overweight
2023-12-13	Iniziato	Wolfe Research	Peer Perform
2023-11-17	Aggiornamento	UBS	Neutral → Buy
2023-10-31	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2023-09-28	Iniziato	Bernstein	Outperform
2023-07-05	Ripresa	JP Morgan	Overweight
2023-06-30	Iniziato	Goldman	Buy
2023-05-10	Iniziato	Barclays	Equal Weight
2023-03-31	Aggiornamento	TD Cowen	Market Perform → Outperform
2023-02-02	Iniziato	UBS	Neutral
2023-01-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-01-05	Iniziato	Scotiabank	Sector Outperform
2022-01-21	Ripresa	Cantor Fitzgerald	Overweight
2022-01-06	Ripresa	Piper Sandler	Neutral
2021-10-15	Ripresa	Cowen	Market Perform
2021-09-27	Iniziato	Canaccord Genuity	Buy
2021-02-11	Aggiornamento	Piper Sandler	Neutral → Overweight
2020-11-03	Downgrade	Piper Sandler	Overweight → Neutral
2020-10-02	Aggiornamento	JP Morgan	Neutral → Overweight
2020-09-09	Iniziato	Morgan Stanley	Equal-Weight
2020-06-02	Ripresa	Cantor Fitzgerald	Overweight
2020-03-09	Ripresa	Cantor Fitzgerald	Overweight
2019-10-15	Aggiornamento	Piper Jaffray	Neutral → Overweight
2019-04-02	Downgrade	Stephens	Overweight → Equal-Weight
2018-10-19	Iniziato	Cowen	Outperform
2017-11-03	Downgrade	First Analysis Sec	Overweight → Equal-Weight
2017-09-28	Downgrade	CL King	Buy → Neutral
2016-11-03	Reiterato	Cantor Fitzgerald	Buy
2016-06-27	Iniziato	CL King	Buy
2016-04-15	Iniziato	First Analysis Sec	Overweight
2016-02-04	Downgrade	Piper Jaffray	Overweight → Neutral
2016-01-04	Reiterato	Cantor Fitzgerald	Buy
2015-10-23	Aggiornamento	Piper Jaffray	Neutral → Overweight
2015-08-27	Iniziato	Cantor Fitzgerald	Buy
2015-02-04	Reiterato	Maxim Group	Buy
2013-09-26	Reiterato	Maxim Group	Buy
2013-01-14	Reiterato	Maxim Group	Buy

Mostra tutto

Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie

06:15 AM

Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know - Yahoo Finance

06:15 AM

09:08 AM

How to build a more competitive grant proposal without losing your research time to it - PacBio

09:08 AM

Sep 04, 2026

Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue? - Eastern Progress

Sep 04, 2026

PacBio to Participate in the Morgan Stanley 24?? Annual Global Healthcare Conference - marketscreener.com

Sep 04, 2026

PACB stock gains as PacBio highlights sequencing strength ahead Morgan Stanley conference - ad-hoc-news.de

Sep 04, 2026

Sep 03, 2026

PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference - marketscreener.com

Sep 03, 2026

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead? - TradingView

Sep 03, 2026

Sep 02, 2026

PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test - TradingView

Sep 02, 2026

3 Reasons to Sell PACB and 1 Stock to Buy Instead - Yahoo Finance

Sep 02, 2026

Aug 29, 2026

Pacific Biosciences (PACB) Tumbles 9.7% to $1.40, Nears Critical Support at $1.33Stock News - vinanet.vn

Aug 29, 2026

Aug 28, 2026

Pacific Biosciences of California (PACB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Aug 28, 2026

Aug 25, 2026

PACB Stock Pops As New CEO Backs Powerful Vega Upgrade - StocksToTrade

Aug 25, 2026

Aug 21, 2026

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Reduce" by Analysts - MarketBeat

Aug 21, 2026

Aug 19, 2026

Pacific (PACB) Earnings Update: EPS Misses Its Estimate on the Day; Trading Response: Shares Close 11.40% Higher in Latest TradingEarnings Weakness Phase - Vinanet

Aug 19, 2026

Pacific Biosciences CEO Mark van Oene sells $30,409 in stock By Investing.com - Investing.com South Africa

Aug 19, 2026

Pacific Biosciences of California (PACB) Institutional Ownership 2026 - MarketBeat

Aug 19, 2026

Aug 18, 2026

Pacific Biosciences CEO Mark van Oene sells $30,409 in stock - Investing.com

Aug 18, 2026

Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells 26,911 Shares of Stock - MarketBeat

Aug 18, 2026

PacBio (NASDAQ: PACB) CEO share sale covers RSU tax withholding - Stock Titan

Aug 18, 2026

Aug 17, 2026

Pacific Biosciences of California Inc (HAM:P09) Stock Price, Trades & News - GuruFocus

Aug 17, 2026